Celsius Therapeutics was a biotechnology company that leveraged single-cell RNA sequencing and genomic analysis to identify novel drug targets and develop precision medicines for complex diseases including autoimmunity and cancer. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company built a human tissue-based platform combining scRNA-seq with machine learning to characterize disease biology at the cellular level. Celsius was acquired by AbbVie in June 2024.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account